Arixtra and Methylprednisolone drug interactions - a phase IV clinical study of FDA data


Drug interactions are reported among 44 people who take Arixtra and Methylprednisolone. Common interactions include skin exfoliation among females, and sepsis among males.

The phase IV clinical study analyzes what interactions people who take Arixtra and Methylprednisolone have. It is created by eHealthMe based on reports from the FDA, and is updated regularly. You may use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 700+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Oct, 02, 2023

44 people who take Arixtra and Methylprednisolone together, and have interactions are studied.

What is Arixtra?

Arixtra has active ingredients of fondaparinux sodium. It is used in deep venous thrombosis. Currently, eHealthMe is studying from 9,694 Arixtra users.

What is Methylprednisolone?

Methylprednisolone has active ingredients of methylprednisolone. It is used in inflammation. Currently, eHealthMe is studying from 49,469 Methylprednisolone users.

Number of Arixtra and Methylprednisolone reports submitted per year:

Arixtra and Methylprednisolone drug interactions.

Common Arixtra and Methylprednisolone drug interactions by gender *:


  1. Skin exfoliation
  2. Thrombophlebitis superficial
  3. Thrombosis
  4. Colitis
  5. Diarrhoea
  6. Vascular occlusion
  7. Pancytopenia
  8. Cerebral haemorrhage
  9. Respiratory failure
  10. Large intestinal haemorrhage


  1. Sepsis
  2. Rash erythematous
  3. Disease progression
  4. Fluid retention
  5. Ileus paralytic
  6. Large intestinal haemorrhage
  7. Neoplasm malignant
  8. Pancytopenia
  9. Paresis
  10. Sensory loss

Common Arixtra and Methylprednisolone drug interactions by age *:












  1. Febrile bone marrow aplasia
  2. Haematoma
  3. Pelvic venous thrombosis
  4. Pulmonary embolism
  5. Purpura
  6. Thrombocytopenia
  7. Thrombophlebitis superficial


  1. Diarrhoea
  2. Colitis
  3. Vascular occlusion
  4. Large intestinal haemorrhage
  5. Sensory loss
  6. Pancytopenia
  7. Neoplasm malignant
  8. Vomiting
  9. Disease progression
  10. Paresis


  1. Sepsis
  2. Haematoma
  3. Encephalopathy
  4. Haemoglobin decreased
  5. Neutropenia
  6. Platelet count decreased
  7. Systemic candida
  8. Urinary tract disorder
  9. Anaemia
  10. Anticoagulation drug level below therapeutic

Common conditions people have *:

  1. Peripheral Arterial Occlusive Disease (reproducible ischemic muscle pain): 8 people, 18.18%
  2. Malignant Melanoma (skin cancer rises from melancytes): 8 people, 18.18%
  3. Diarrhea: 8 people, 18.18%
  4. Pain: 7 people, 15.91%
  5. Squamous Cell Carcinoma (a cancer of a kind of epithelial cell): 4 people, 9.09%
  6. Progressive Multiple Sclerosis (chronic autoimmune disease of the central nervous system in which gradual destruction of myelin occurs in patches throughout the brain or spinal cord): 4 people, 9.09%
  7. Stable Angina (a constant chest pain): 3 people, 6.82%
  8. Epstein-Barr Virus Infection: 3 people, 6.82%
  9. Epilepsy (common and diverse set of chronic neurological disorders characterized by seizures): 3 people, 6.82%

* Approximation only. Some reports may have incomplete information.

Do you take Arixtra and Methylprednisolone?

Personalize this study to your gender and age

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related studies

Drug side effects by duration, gender and age:

Common Arixtra drug interactions:

Browse interactions between Arixtra and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Methylprednisolone drug interactions:

Browse interactions between Methylprednisolone and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on fondaparinux sodium and methylprednisolone (the active ingredients of Arixtra and Methylprednisolone, respectively), and Arixtra and Methylprednisolone (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study. Patients in the study may take other drugs besides Arixtra and Methylprednisolone.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 700+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).


WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: